A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the ...
By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker ...
AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of ...
Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...
A groundbreaking multi-stakeholder report reveals that transitioning to Non-Animal Methods (NAMs) can reduce drug development ...
In the pursuit of solutions to complex global challenges including disease, energy demands, and climate change, scientific ...
More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...
Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity February ...
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...
On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...
Interpretable AI model could offer new insights into why medicines cause certain side effects, helping to improve future drug safety predictions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results